Pretax profit increases 13% to $364m at Irish arm of Teva
Pharmaceutical firm is one of the largest employers in the southeast
Drug distributors to pay up to $1.1bn in New York opioid case settlement
Landmark nationwide deal with distributors and Johnson & johnson likely shortly
Teva, Cephalon fined €60.5m for delay to sales of sleep-disorder drug
Fine ends nine-year probe and concludes anti-trust crusade against pay-for-delay deals
US opioid epidemic: drug companies reach $260m settlement
Four firms avert federal trial, with Walgreens Boots Alliance now the sole defendant
US states file suit accusing drugs firms of inflating prices by 1,000%
Teva USA says it intends to fight the allegations made in complaint by 44 US states
Teva shares plunge after drugmaker misses revenue forecasts
Company lifts guidance for the year but still seeks new drivers of growth
Court refuses injunctions in pharma patent case
Teva sought orders restraining Galway-based Mylan from making MS drug
Generic drugs giant Teva to cut workforce by more than 25%
No decision on future of Irish plants which employ about 580
Drugmaker Endo reports higher-than-expected quarterly profit
Total revenue falls due to weakness in company’s US generics business
Drug firm Teva predicts 2017 revenue and profit below estimates
Israel company expects earnings per share of $4.90-$5.30 on revenue of $23.8bn-$24.5bn
Teva to pay US $519m over foreign bribery charges
Settlement relates to behaviour in Ukraine, Mexico and Russia by largest generic pharma
Teva to sell Allergan’s generics business in Ireland and UK for £603m
Sale part of Teva’s EU deal to approve purchase of Allergan’s overall generics interests
Allergan revenue disappoints as Alzheimer drug loses exclusivity
Irish drugmaker formerly known as Actavis cuts full-year adjusted net revenue forecast
Allergan profit beats on strong sales of Botox and Restasis
Irish based company reports better-than-expected quarterly profits
Pfizer in merger talks with Botox-maker Allergan
Takeover could offer tax advantages given that Allergan is based in Dublin
Mylan to ask Perrigo shareholders to accept $27.1bn takeover
Dublin-based Perrigo’s board have previously refused bid
Mylan and Perrigo each win backing in hostile takeover battle
Proxy advisor ISS says bid for Dublin-based Perrigo too expensive, but Mylan investor and hedge fund Paulson
Mylan may sweeten terms for Perrigo deal
Pharma group chairman told investors he may sweeten the company’s offer for Irish headquartered company by adding terms to reduce the risk to its shareholders
Generic drugmaker Mylan goes hostile in bid for Perrigo
Irish target rejects latest offer, saying it values business at less than initial approach
Perrigo rejects $29bn bid from generics group Mylan
Irish company says unsolicited bid undervalues company and does not reflect growth potential
Generic drugmaker Teva makes $40bn offer for rival Mylan
Mylan adopts poison-pill defence and renews commitment to Perrigo deal
Teva makes $82 per share offer for rival Mylan
Generic drugmaker makes bid at 48 per cent premium to stock price
Teva to buy Auspex Pharmaceuticals in $3.5 billion deal
Firm bolsters its business of making drugs to treat disease of the central nervous system
Teva Pharmaceutical chief executive resigns
Shares in Tel Aviv fell 6.2 per cent after announcement made
Managing litigation for your business
Good managers can reduce the conflict that leads to costly lawyers and courts
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices